Latest News
FDA Accepts Scholar Rock’s Biologics License Application (BLA) to Review Apitegromab for SMA
Today, Scholar Rock shared that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational treatment for spinal muscular atrophy (SMA), with a […]
Cure SMA Releases Policy Brief Highlighting Importance of Medicaid Home Care for People with SMA
Cure SMA has released a new policy brief highlighting the essential role Medicaid-funded home care plays in the lives of individuals with spinal muscular atrophy (SMA), a rare neuromuscular disease. […]
The 10th Annual Cure SMA Community Update Survey Is Now Available
Since 2017, 3,200 people have shared their experiences and unmet needs through the Cure SMA Community Update Survey. The Community Update Survey is an annual online questionnaire Cure SMA uses […]
Breakthroughs Built Together: Help Cure SMA Close a Critical Research Funding Gap
This spring, we’re asking our community to help us invest $1 million in basic research by June 30. Every breakthrough in spinal muscular atrophy (SMA) research has one thing in common. It wasn’t built […]
Cure SMA Launches Phase 11 SMA Industry Collaboration
Cure SMA is pleased to announce the launch of Phase 11 initiates for the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, […]
Scholar Rock Resubmits Biologics License Application (BLA) for Apitegromab to the FDA
Today, Scholar Rock announced that it has resubmitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for apitegromab, an investigational therapy for the treatment of people […]